Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cardinal health - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - adjunctive therapy lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: monotherapy lamotrigine tablets are indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed). safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from aeds other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. lamotrigine tablets are indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [see clinical studies (14.2)] . limitations

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cardinal health - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 1 mg - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with - hypersensitivity to benzodiazepines or to any components of the formulation. - acute narrow-angle glaucoma.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cardinal health - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 0.5 mg - lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam tablets are contraindicated in patients with

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cardinal health - temazepam (unii: chb1qd2qss) (temazepam - unii:chb1qd2qss) - temazepam 15 mg - temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days). for patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days). the clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. benzodiazepines may cause fetal harm when administered to a pregnant woman. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. reproduction studies in animals with temazepam were performed in rats and rabbits. in a perinatal-postnatal study in rats, oral doses of 60 mg/kg/day result

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cardinal health - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the apa diagnostic and statistical manual [dsm-iii-r] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of 6 months or longer, during which the person has been bothered more days than not by these concerns. at least 6 of the following 18 symptoms are often present in these patients: motor tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); autonomic hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or l

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cardinal health - roflumilast (unii: 0p6c6zop5u) (roflumilast - unii:0p6c6zop5u) - roflumilast 500 ug - daliresp® is indicated as a treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations. limitations of use daliresp is not a bronchodilator and is not indicated for the relief of acute bronchospasm. the use of daliresp is contraindicated in the following condition: moderate to severe liver impairment (child-pugh b or c) [see clinical pharmacology (12.3) and use in special populations (8.6) ]. teratogenic effects: pregnancy category c: there are no adequate and well controlled studies of daliresp in pregnant women. daliresp was not teratogenic in mice, rats, or rabbits. daliresp should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. daliresp induced stillbirth and decreased pup viability in mice at doses corresponding to approximately 16 and 49 times, respectively, the maximum recommended human dose (mrhd) (on a mg/m2 basis at maternal doses > 2 mg/kg/day and 6 mg/kg/day, r

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cardinal health australia 503 pty ltd - 44977 - light system sterile handle cover, single-use - intended to be used with surgical lights to provide a sterile interface with operating room personnel.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cardinal health australia 503 pty ltd - 35035 - electrode, electrocardiograph, single use - intended to be applied to the surface of the body to enable transmission of electrical signals (to a processor) from the intact skin.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cardinal health australia 503 pty ltd - 47408 - negative-pressure wound therapy system pump - it is indicated for the application of continuous or intermittent negative pressure wound therapy. the device may promote wound healing by the removal of fluids, including wound exudates, irrigation fluids, body fluids and infectious materials. it is intended for patients with chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. it is intended for use in acute, extended and home care settings.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cardinal health australia 503 pty ltd - 57982 - urethral catheter holder - leg straps are intended to hold the urine leg bags securely to the patient.